MYBIOPASSPORT
5.2.2021 08:50:10 CET | Business Wire | Press release
Mybiopassport.com, the platform set-up by CoreMedica Europe, a Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of their “Nutritional Profile” and “Sport Performance Profile” tests, which will complement their current “Immunity Profile” and “COVID-19” tests
Mybiopassport proposes at-home blood collection tests to help anyone become the “heroes of their own health” . Individuals can now collect only a few drops of blood at their homes and send their samples by regular prepaid mail to the company’s authorized laboratory located in Geneva, Switzerland, to determine the levels of key biomarkers known to support sport performance, a healthy nutrition, and the immune system. The tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal through a simple sign-up procedure.
The purposes of these tests are as follows :
- Nutritional – A tool informing the client of their current nutritional status based on past habits and providing personalized recommendations on how to correct any deficiencies or excesses through nutrition. The first of its kind, this test provides information about the levels of micronutrients belonging to all four classes of essential micronutrients, namely vitamins, minerals, fatty acids and amino acids. These are all linked to specific bodily functions (fatigue, sleep, anxiety, etc.) making this test the most comprehensive and informative on the market.
- Sport Performance – A tool developed to help amateur and professional athletes determine if their performance related biomarkers are at their optimal levels to allow them to perform at their best. All the biomarkers tested are linked to specific sport related functions, such as recovery , muscle growth, energy delivery, or even as specific as exercise induced joint pain.
- Immunity - The COVID-19 & Immunity Profile, powered by Mybiopassport, lets clients know if they were previously infected by the SARS-CoV-2 virus through the development of specific antibodies. More importantly, the Immunity Profile test also delivers actionable nutritional recommendations based on a set of key biomarkers known to support the immune system, including vitamin D, zinc and magnesium.
It is now widely accepted that the first step towards a healthy body is good nutrition. Indeed, multiple studies have shown that the risks of developing cardiovascular disease, diabetes, and even dementia are strongly linked to long-term nutritional habits. Recent scientific reports and publications have highlighted the role of nutrition, optimal micronutrient status and a well-functioning immune system as a modifiable factor in reducing the risk of viral infections and their severity. These publications highlight the key role of a good nutritional status for a well-functioning immune system.
Mybiopassport’s mission is clearly to democratize access to specific health-related information and to give people the means to not only understand, but also act on their health through nutrition and lifestyle. They firmly believe in individual empowerment and that the access to personalized health information is the first step towards preventing potential health issues.
Mybiopassport relies on a unique technology in the personalized analysis of biological data on three main axes:
- Pre-analytical with the easy collection of a few drops of blood anywhere, at any time and by anyone,
- Analytical, with the measurement of an unprecedentedly large number of phenotypic biomarkers, via a unique know-how developed over several years,
- Post-analytical, providing not only a scientific result, but personalized recommendations based on a patented technology applied in several fields, such as immunity, nutrition, sport, longevity and anti-aging.
Individuals can now collect a few drops of blood from the comfort and safety of their homes and send their samples by prepaid regular mail to Mybiopassport’s laboratory in Geneva.
The Nutritional, Sport Performance and Immunity tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal with test results reviewed by health professionals.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a person’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018 and its recent acquisition by Swiss Medical Group Holding Luxembourg SA, CoreMedica Europe expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204006231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance29.4.2026 14:06:00 CEST | Press release
Tecnotree, a global digital platform and services provider for AI-enabled 5G and cloud-native technologies, today announced its financial results for the first quarter of 2026, demonstrating stable revenue, strong profitability, and a robust order backlog despite geopolitical uncertainties across global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429319948/en/ Tecnotree Reports Stable Revenue and Strong Profitability in Q1 2026 and Maintains Full-Year Guidance Key Financial Highlights – Q1 2026 Revenue of EUR 16.8 million (16.9), revenue in constant currency EUR 17.1 million, +1.0% YoY. EBIT of EUR 4.6 million (4.5), +1.8% YoY. EBIT margin of 27.4% (26.9%), +50 basis points YoY. Foreign exchange (FX) gains EUR 1.0 million (-1.4). Net income EUR 2.1 million (1.5), +36.5% YoY. Free cash flow (FCF) EUR 0.2 million (1.0). Earnings per share (EPS) EUR 0.1 (0.1). Order book at the end of the period EUR 105.4 million
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation29.4.2026 14:00:00 CEST | Press release
Agentic automation platform enables companies to control, govern and accelerate enterprise-wide adoption of AI SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of SS&C Blue Prism WorkHQ, its agentic automation platform designed to help enterprises operationalize agentic AI safely, transparently and with full control of end-to-end workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429512507/en/ Unveiled at a live event at Nasdaq in New York City, WorkHQ introduces a unified control plane orchestrating people, AI agents, APIs and digital workers into a single governed environment. SS&C developed WorkHQ based on its own experience operating at scale across regulated industries. Today, SS&C supports more than 23,000 customers globally with the help of 4,000+ digital workers and more than 50 AI agents. These efforts have enabled SS&C to significantly improve operational efficiency in key proces
Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea29.4.2026 14:00:00 CEST | Press release
New facility brings deep expertise closer to Asian customers, strengthening Ecolab’s global network Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide. Today, Ecolab Life Sciences announced the opening of a new Bioprocessing Applications Lab (BPAL) in Dongtan, Korea, its first bioprocessing facility in Asia. The new center further strengthens the company’s global Life Sciences footprint and supports customers operating in one of the world’s most advanced biopharmaceutical manufacturing markets. The Korea BPAL supports a full range of process development activities from early-stage testing through studies that replicate manufacturing at scale, building on Ecolab’s established bioprocessing applications network in the United States and the United Kingdom. The facility enables hands-on collaboration with Ecolab’s bioprocessing experts t
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
